Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice

BACKGROUND: Current anti-cancer therapeutic antibodies that are used in the clinic are predominantly humanized or fully human immunoglobulin G1 (IgG1). These antibodies bind with high affinity to the target antigen and are efficient in activating the immune system via IgG Fc receptors and/or complem...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Autores principales: Braster, Rens, Grewal, Simran, Visser, Remco, Einarsdottir, Helga K., van Egmond, Marjolein, Vidarsson, Gestur, Bögels, Marijn
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5438146/
https://ncbi.nlm.nih.gov/pubmed/28542406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0177736
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares